A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2912 participants.
Also called NCT05952856
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,912 participants
- Sponsor
- Registry
-
NCT05952856 -
2022-502777-42-01 -
U1111-1285-4164 -
jRCT2031230320
-
- Other papers using this trial's data
- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, China, Colombia, Germany, Israel, Italy, Japan, Mexico, South Africa, South Korea, Spain, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT05952856. Randomized; triple masking; primary purpose treatment. Start 2023-08-10 (actual); primary completion 2025-07-28 (actual). Results posted on 2026-08-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
- Condition
- Hypercholesterolemia
- Condition
- Familial Hypercholesterolemia
- Intervention (Drug)
- Enlicitide Decanoate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct05952856- Content hash
53895bb22e72143c4122cee4d4a82689353d0fc7077c8c0a803f8dd8eb6573e5